Abstract: The present invention relates to a combination of elafibranor with either riboflavin or DHA as antiviral agent. The bacteriophage T4 titer on E. coli that is increased by elafibranor in comparison to an untreated control is reversed by the combination of elafibranor with riboflavin or elafibranor with DHA. Therefore, these combinations decrease adverse side effects of elafibranor on the gut microbiota.

Abstract: The present invention relates to systemic detoxification and chronic inflammation by using extract fractions of Laurus nobilis, that lead to a decrease of anti-inflammatory markers in human lung cell lines and the activation of the Nrf2 pathway, which is a crucial element in intracellular detoxification pathways, decreases the expression of inflammatory cytokines. Therefore, the extract can be used to reduce the adverse effects of air pollution generally (and especially of particulate air pollution), which includes: cardiovascular problems, respiratory diseases, and chronic inflammation of tissues that come into contact with air borne particles.

Abstract: Riboflavin can have a beneficial effect in supporting bowel health in healthy people. Specifically it can relieve diarrhea or constipation, regulate bowel movement frequency, and regulating bowel movement urgency. The dosage brings the daily intake of riboflavin (consumed by diet and by supplement) above the RDA.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: The present invention relates to systemic detoxification by using extracts of Withania somnifera (ashwagandha) and its Nrf2-activating components withaferin-A, 12-deoxywithastramonolide, and Quresimine A. When ingested, the transcription factor Nrf2, which is a crucial element in intracellular detoxification pathways, leads to elimination of potentially toxic compounds. In parallel, the expression of inflammatory cytokines is decreased. Therefore, the extract can be used to reduce the adverse effects of air pollution generally (and especially of particulate air pollution), which includes: cardiovascular problems, respiratory diseases, and chronic inflammation of tissues that come into contact with air borne particles.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: A method of treatment and/or prevention of age-related macular degeneration (AMD) wherein, in a first step, the need for treatment or susceptibility to AMD is determined for an individual and, in a second step, a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual. The invention also provides a method of determining a substance to be administered to an individual, which individual may be susceptible of having age-related macular degeneration (or an age-related macular degeneration-related disorder) comprising: a) determining the susceptibility of the individual to age-related macular degeneration (usually genetically, by detection of an SNP); and b) on the basis of the determination in a), identifying a substance capable of preventing or treating age-related macular degeneration in that individual.